Observational studyCancer immunology, immunotherapy : CII2026
Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis.
Observational study in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe optimal sequence of administering immune checkpoint inhibitors (ICIs) and chemotherapy in advanced esophageal cancer (EC) and gastric cancer (GC) remains to be established. Understanding how this sequencing affects overall survival (OS) is crucial for optimizing treatment strategies.
methodsThis multicenter study enrolled 334 patients diagnosed with advanced EC or GC between January 2018 and October 2024. To reduce confounding biases, propensity score matching (PSM) was applied, resulting in 292 matched patients categorized into two groups, including those receiving ICIs first (IF) and those receiving chemotherapy first (CF).
resultsFollowing PSM, Kaplan-Meier analysis showed that the CF group had a significantly prolonged median OS compared to the IF group (16.80 vs. 14.60 months; p = 0.014). These findings were further corroborated in the unmatched cohort (16.60 vs. 14.60 months; p = 0.012). Multivariable analysis identified ECOG performance status, PD-L1 expression, antibiotic use, and line of ICI treatment as independent prognostic factors, whereas the immunochemotherapy administration sequence did not retain independent prognostic significance. Subgroup analysis revealed that among patients receiving first-line immunochemotherapy, those in the CF group had significantly longer OS (16.50 vs. 12.30 months; p = 0.004), with no significant difference observed for those beyond first-line treatment (p = 0.862). The objective response rate and disease control rate were comparable between the two groups.
conclusionsThis study suggests that administering chemotherapy prior to immunotherapy appears to improve OS in patients with advanced EC and GC, particularly when initiated as first-line treatment. These findings highlight the need for further research into biomarkers and personalized treatment strategies to enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.